ArticleJournal of neuro-oncology2016

Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.

D H Heiland et al.PubMed ↗Publisher ↗

No numbers read from the abstract.